CHICAGO, July 30, 2026
EVERSANA has been selected by Innovacell Inc. as its exclusive U.S. commercialization partner to support the advancement and anticipated launch of ICEF15, an investigational regenerative cell therapy designed to treat urgent fecal incontinence. The strategic collaboration combines EVERSANA’s comprehensive commercialization platform with Innovacell’s expertise in regenerative medicine, providing end-to-end support as ICEF15 progresses toward commercialization in the United States. Through the partnership, EVERSANA will deliver integrated services spanning pre-launch planning, market access, patient engagement, data analytics, field deployment, agency support, and distribution, helping prepare the novel therapy for successful market entry. The announcement underscores the growing importance of specialized commercialization partners in accelerating access to advanced cell and gene therapies, while reinforcing confidence in ICEF15, which is currently being evaluated in a multi-regional Phase III clinical trial.
Strategic Commercialization Partnership Supports U.S. Cell Therapy Launch
The collaboration positions EVERSANA as the exclusive commercialization partner responsible for supporting Innovacell’s entry into the U.S. regenerative medicine market. Leveraging its global expertise in cell and gene therapy commercialization, EVERSANA will provide a full range of commercial services designed to navigate the complex regulatory, reimbursement, and market access landscape associated with advanced therapies. The company’s integrated commercialization platform includes strategic launch planning, payer engagement, medical communications, patient services, distribution logistics, and healthcare provider support, enabling Innovacell to establish a strong commercial foundation for ICEF15. The partnership reflects increasing demand for specialized commercialization expertise as biotechnology companies transition innovative therapies from late-stage clinical development to commercial availability while ensuring efficient patient access and healthcare system integration.
ICEF15 Aims to Transform Treatment for Urgent Fecal Incontinence
ICEF15 is an investigational autologous regenerative cell therapy developed to restore damaged muscle tissue through the localized administration of a patient’s own skeletal myoblasts. The therapy is being developed to treat urgent fecal incontinence, a chronic condition that significantly impacts quality of life and currently has limited treatment options. By regenerating muscle function rather than simply managing symptoms, ICEF15 has the potential to introduce a new therapeutic approach within regenerative medicine. The therapy is currently being evaluated in the Fidelia Phase III clinical trial, a multi-regional study conducted across the United States, Japan, and 11 European countries. Innovacell has previously completed multiple successful clinical studies in Europe, including Phase IIb trials evaluating ICEF15 for urgent fecal incontinence and ICES13 for stress urinary incontinence, providing a strong clinical foundation for continued late-stage development and future regulatory submissions.
Advertisement
Regenerative Medicine Continues Expanding Global Commercial Potential
The EVERSANA-Innovacell partnership reflects the rapidly growing commercial landscape for regenerative medicine and cell therapies, where innovative technologies are increasingly moving toward global commercialization. Unlike conventional pharmaceuticals, advanced therapies require specialized commercialization strategies that address manufacturing complexity, physician education, patient support, reimbursement planning, and distribution logistics. EVERSANA’s experience supporting numerous cell and gene therapy launches across North America and Europe provides Innovacell with an established infrastructure capable of accelerating patient access while supporting successful product adoption. As Innovacell continues advancing its pipeline of regenerative medicine products targeting fecal incontinence and stress urinary incontinence, the collaboration represents an important milestone in expanding access to innovative therapies designed to restore tissue function and improve patient quality of life. The agreement also highlights continued investment across the biotechnology industry in strategic partnerships that bridge clinical development and successful commercialization of next-generation regenerative therapies.
Source: EVERSANA, Innovacell press release
